Search research articles
Contact Us
Filters
Showing results (341-350 of 359) with videos related to
Page
of 36
Sort By:
JAMA Network Open
|
November 7, 2024
Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial
Hui Tan, Yushen Gu, Yan Xiu, et al.
Leukemia & Lymphoma
|
May 8, 2019
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG)
Shu-Nan Qi, Li-Ming Xu, Zhi-Yong Yuan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 10, 2018
Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)
Xiu-Wen Deng, Jun-Xin Wu, Tao Wu, et al.
Cancer Medicine
|
October 26, 2018
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)
Bo Chen, Su-Yu Zhu, Mei Shi, et al.
Aging
|
October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)
Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open
|
March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma
Xin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances
|
September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group
Tao Wu, Yong Yang, Su-Yu Zhu, et al.
Cancer Reports (Hoboken, N.J.)
|
March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma
Jia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology
|
January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis
Jing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Leukemia
|
August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study
Yong Yang, Ying Wang, Xin Liu, et al.
Page
of 36
Search research articles
Search
Showing results (341-350 of 359) with videos related to
Sort By:
Page
of 36
JAMA Network Open
|
November 7, 2024
Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial
Hui Tan, Yushen Gu, Yan Xiu, et al.
Leukemia & Lymphoma
|
May 8, 2019
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG)
Shu-Nan Qi, Li-Ming Xu, Zhi-Yong Yuan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 10, 2018
Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)
Xiu-Wen Deng, Jun-Xin Wu, Tao Wu, et al.
Cancer Medicine
|
October 26, 2018
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)
Bo Chen, Su-Yu Zhu, Mei Shi, et al.
Aging
|
October 7, 2019
Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG)
Wei-Xin Liu, Mei Shi, Hang Su, et al.
JAMA Network Open
|
March 2, 2019
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma
Xin Liu, Tao Wu, Su-Yu Zhu, et al.
Blood Advances
|
September 23, 2018
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group
Tao Wu, Yong Yang, Su-Yu Zhu, et al.
Cancer Reports (Hoboken, N.J.)
|
March 15, 2023
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma
Jia-Xin Liu, Xin Liu, Yong Yang, et al.
JCO Global Oncology
|
January 15, 2026
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis
Jing Yang, Qiu-Zi Zhong, Li-Ting Qian, et al.
Leukemia
|
August 3, 2021
Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study
Yong Yang, Ying Wang, Xin Liu, et al.
Page
of 36